Vidarabine, an anti-herpes agent, prevents occlusal-disharmony-induced cardiac dysfunction in mice

Table 1 Cardiac function assessed by echocardiography at 2 weeks after BO

	Control	BO	V	BO + V
n	6	6	7	6
IVSTd	0.57 ± 0.06	0.53 ± 0.08	0.59 ± 0.08	0.51 ± 0.05
LVSTs	0.95 ± 0.07	0.86 ± 0.03	0.92 ± 0.07	0.84 ± 0.04^*
LVEDV	0.21 ± 0.03	0.21 ± 0.01	0.21 ± 0.03	0.19 ± 0.03
CO	57 ± 8.6	54 ± 4.5	60 ± 8.9	48 ± 9.6
HR	468 ± 57	468 ± 20	473 ± 62	434 ± 73
LVIDd	4.4 ± 0.2	4.4 ± 0.1	4.4 ± 0.3	4.2 ± 0.2
LVIDs	3.0 ± 0.1	3.2 ± 0.1	2.9 ± 0.4	2.9 ± 0.2
ESV	0.07 ± 0.009	0.08 ± 0.009	0.07 ± 0.02	0.06 ± 0.01^#
EF	68 ± 1.1	61 ± 3.0^***	67 ± 2.3	66 ± 1.4^##
LVPWTd	0.56 ± 0.03	0.54 ± 0.04	0.59 ± 0.04	0.56 ± 0.04
LVPWTs	0.91 ± 0.06	0.86 ± 0.06	0.91 ± 0.07	0.84 ± 0.09
SV	0.14 ± 0.02	0.13 ± 0.01	0.14 ± 0.02	0.12 ± 0.02
%FS	33 ± 0.8	28 ± 1.9^***	32 ± 1.5	31 ± 1.0^##

IVSTd (mm): interventricular septum thickness at end-diastole, LVSTs (mm): interventricular septum thickness at end-systole, LVEDV (mL): left ventricular end-diastolic volume, CO (mL/min): cardiac output, LVIDd (mm): left ventricular internal dimension at end-diastole, LVIDs (mm): left ventricular internal dimension at end-diastole, ESV (mL): left ventricular end-systolic volume, EF (%): ejection fraction, LVPWTd (mm): left ventricular posterior wall thickness at end-diastole, LVPWTs (mm): left ventricular posterior wall thickness at end-diastole, SV (mL): stroke volume, %FS (%): % fractional shortening
***P < 0.001 vs. Control
^##P < 0.05 vs. BO
^#P < 0.05 vs. BO

ISSN: 1880-6562